Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Baylor University Medical Center, Dallas
Researchers describe findings in transplant medicine studies
November 4th, 2005
Transplant medicine research advances have been reported from the United States and Spain. Study 1: Human hepatitis C immune globulin appears safe in liver transplant recipients. According to a study from the United States, "chronic hepatitis C is the most common indication for liver transplantation, but viral recurrence is universal and progressive graft injury occurs in most recipients. Our aim was to assess the safety, pharmacokinetics (PK), and antiviral effects of high doses of a human hepatitis C antibody enriched immune globulin product (HCIG) in patients undergoing liver transplantation for chronic hepatitis C." "This was...
Source: Biotech Law Weekly (2005-11-04)
|
